FGF-21 Level is higher in patients with breast cancer, a candidate for a new biomarker?

Year 2024, , 282 - 285, 29.07.2024

Zeynep Şahiner , Anara Karaca , Filiz Bakar Ateş , Gökhan Giray Akgül , Mehmet Ali Gülçelik , Neşe Ersöz Gülçelik

https://doi.org/10.38053/acmj.1498225

Abstract

Aims: Fibroblast Growth Factor 21 (FGF-21) is a member of the FGF family involved in biological processes such as embryonic development. cell growth. morphogenesis. tissue repair. tumour growth and invasion. with mitogenic and cytogenetic activity at 19q13.33.Breast cancer is a deadly and increasing disease in women. and recent studies have shown a relationship between some cancers. including breast cancer. and hormones secreted from adipose tissue.The aim of the present study was the measurement of FGF-21 levels in patients with breast cancer and its association with breast cancer.
Methods: The study included 39 patients with newly diagnosed breast cancer and 39 healthy controls. During the patients’ routine blood tests. a venous blood sample was taken and the serum levels of FGF-21 were determined by ELISA.
Results: Demographic and laboratory data were compared between the newly diagnosed breast cancer group and the control group. The control group consisted of 39 participants with a mean age of 52.49 ± 7.02 years. In the patient group. 39 participants with a mean age of 52.15 ± 6.21 years were included in the study. there was no statistical difference regarding age(p>0.05).In the control group. the mean FGF-21 level was 121.35 ± 88.4 pg/ml. while the mean FGF-21 level in the patient group was 171 ± 117.45 pg/ml. a statistically significant difference was detected(p value=0.036).
Conclusion: FGF-21 is thought to have significant and beneficial effects on glucose. lipid and energy metabolism. as well as slowing the growth of cancer cells. and may later be used as a biological marker for breast cancer.

Keywords

FGF-21, Breast Cancer, Obesity

Ethical Statement

The study was carried out with the permission of Ankara Research and Training Center Ethics Committee (Date: 04.05.2016, Decision No: 2016- 5378).

Thanks

Dear Editor, We would be very happy if you accept our work, on which we have worked hard, for publication in your journal.I am also an active reviewer of the dergipark. Best Regards..

References

• Xue F, Michels KB. Diabetes metabolic syndrome and breast cancer: a review of the current evidence. Am J Clin Nutr. 2007;86(3):823-835.
• Balkau B, Valensi P, Eschwège E, Slama G. A review of the metabolic syndrome. Diabetes Metab. 2007;33(6):405-413.
• Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008;44(2):293-297.
• Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer. 2006;119(1):236-238.
• Falk LE, Liu J, Li YI, Lewis MJ, Demark-WW, Hurst DR. Globular adiponectin enhances invasion in human breast cancer cells. Oncol Lett. 2016;11(1):633-641.
• Fisher FM, Kleiner S, Douris N, et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012;26(3):271-281.
• Luo Y, McKeehan WL, Stressed liver and muscle call on adipocytes with FGF21.Front Endocrinol. 2013;18(4):194.
• Abdulrahman GO Jr, Rahman GA. Epidemiology of breast cancer in europe and Africa. J Cancer Epidemiol. 2012;27:915610. doi: 10.1155/2012/915610
• Bjorge T, Lukanova A, Jonsson H, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1737-1745.
• Lin ZL, Tian H, Lam KS, Lin S. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17(5):779-789.
• Fukumoto S. Actions and mode of actions of FGF19 subfamily members. Endocr J. 2008;55(1):23-31.
• Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-1635.
• Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246-1253.
• Huang X,Yu C, Jin C, et al. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog. 2006;45(12):934-942.
• Ping Q, Yan R, Cheng X, et al. Cancer-associated fibroblasts: overview, progress, challenges, and directions. Cancer Gene Ther. 2021;28(9):984-999. Epub Erratum in: Cancer Gene Ther. 2021;28(9):1074.
• Ewendt F, Feger M, Föller M. Role of fibroblast growth factor 23 (FGF23) and αklotho in cancer. Front Cell Dev Biol. 2021;14(8): 601006.